NCT03513666

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Toripalimab Combined With Pemetrexed Plus Carboplatin for Treatment of Recurrent or Advanced Non-small-cell Lung Cancer With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment：a Multi-center, Single Arm Phase II Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatment：a multi-center, single arm phase II study

Conditions

• NSCLC

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Drug intervention	anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin

Timeline

• Start date: 2018-04-09
• Primary completion: 2022-08-12
• Completion: 2022-08-12
• First posted: 2018-05-01
• Last updated: 2023-08-23

Locations

5 sites across 1 country: China